• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review.新辅助治疗局部晚期乳腺癌病例中影响病理完全缓解的因素:一项综合文献综述
Eur J Breast Health. 2023 Dec 27;20(1):8-14. doi: 10.4274/ejbh.galenos.2023.2023-11-2. eCollection 2024 Jan.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
4
Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.新辅助全身治疗后乳腺癌亚型患者初始临床淋巴结阳性疾病的腋窝病理完全缓解:系统评价和荟萃分析。
JAMA Surg. 2021 Jun 1;156(6):e210891. doi: 10.1001/jamasurg.2021.0891. Epub 2021 Jun 9.
5
6
Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy.局部晚期乳腺癌患者接受新辅助化疗的病理反应与分子亚型的关系。
J Chemother. 2023 Feb;35(1):29-38. doi: 10.1080/1120009X.2022.2043514. Epub 2022 Feb 26.
7
Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.接受新辅助化疗后达到完全病理缓解的乳腺癌患者肿瘤分子亚型、临床分期与腋窝病理反应之间的关联:对腋窝手术降阶梯治疗的潜在意义
Ther Adv Med Oncol. 2021 Feb 26;13:1758835921996673. doi: 10.1177/1758835921996673. eCollection 2021.
8
[Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].[初诊为同侧锁骨上淋巴结转移的乳腺癌新辅助化疗后同侧锁骨上淋巴结病理完全缓解(pCR)的列线图预测模型构建]
Zhonghua Zhong Liu Za Zhi. 2022 Feb 23;44(2):160-166. doi: 10.3760/cma.j.cn112152-20200420-00358.
9
Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index.预测接受新辅助治疗的乳腺癌患者反应的因素及 Ki67 标记指数的作用。
J Coll Physicians Surg Pak. 2023 Aug;33(8):872-878. doi: 10.29271/jcpsp.2023.08.872.
10
[Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].[局部晚期伴腋窝受累乳腺癌新辅助化疗后的腋窝病理反应]
Rev Esp Med Nucl Imagen Mol. 2015 Jul-Aug;34(4):230-5. doi: 10.1016/j.remn.2015.01.005. Epub 2015 Mar 3.

引用本文的文献

1
Predictors of High-Burden Residual Axillary Disease After Neoadjuvant Therapy in Breast Cancer.乳腺癌新辅助治疗后高负担腋窝残留病灶的预测因素
Cancers (Basel). 2025 May 8;17(10):1596. doi: 10.3390/cancers17101596.
2
Dismal pathological response to neoadjuvant chemotherapy in stage III breast cancer patients in Tanzania: A retrospective review.坦桑尼亚III期乳腺癌患者对新辅助化疗的病理反应不佳:一项回顾性研究。
PLoS One. 2025 Apr 23;20(4):e0321187. doi: 10.1371/journal.pone.0321187. eCollection 2025.
3
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.管腔型乳腺癌完全病理缓解的预测因素:Ki67和HER2低表达的影响
Ther Adv Med Oncol. 2024 Dec 23;16:17588359241309169. doi: 10.1177/17588359241309169. eCollection 2024.
4
Comprehensive Axillary Management of Clinically Node-Positive (cN+) Breast Cancer Patients: A Narrative Review on Neoadjuvant Chemotherapy.临床淋巴结阳性(cN+)乳腺癌患者的腋窝综合管理:关于新辅助化疗的叙述性综述
Cancers (Basel). 2024 Sep 30;16(19):3354. doi: 10.3390/cancers16193354.
5
Prognostic Evaluation of Piezo2 Channels in Mammary Gland Carcinoma.Piezo2通道在乳腺癌中的预后评估
Cancers (Basel). 2024 Jun 29;16(13):2413. doi: 10.3390/cancers16132413.

本文引用的文献

1
Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index.预测接受新辅助治疗的乳腺癌患者反应的因素及 Ki67 标记指数的作用。
J Coll Physicians Surg Pak. 2023 Aug;33(8):872-878. doi: 10.29271/jcpsp.2023.08.872.
2
Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis.新辅助全身治疗后对临床淋巴结阴性的HER2阳性和三阴性乳腺癌省略前哨淋巴结活检:一项汇总分析
Cancers (Basel). 2023 Jun 24;15(13):3325. doi: 10.3390/cancers15133325.
3
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.种族和年龄对早期乳腺癌黑人和白人女性新辅助治疗反应和长期结局的影响。
Breast Cancer Res Treat. 2023 Jul;200(1):75-83. doi: 10.1007/s10549-023-06943-x. Epub 2023 Apr 29.
4
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer.接受新辅助化疗的早期乳腺癌患者的病理完全缓解中的种族差异。
JAMA Netw Open. 2023 Mar 1;6(3):e233329. doi: 10.1001/jamanetworkopen.2023.3329.
5
A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy.基于血小板与淋巴细胞比值的列线图预测乳腺癌新辅助化疗后病理完全缓解。
BMC Cancer. 2023 Mar 14;23(1):245. doi: 10.1186/s12885-023-10703-x.
6
New insights into breast microcalcification for poor prognosis: NACT cohort and bone metastasis evaluation cohort.对不良预后的乳腺微钙化的新认识:NACT 队列和骨转移评估队列。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7285-7297. doi: 10.1007/s00432-023-04668-4. Epub 2023 Mar 14.
7
The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.体重指数对乳腺癌患者新辅助化疗反应的预测重要性
Breast Care (Basel). 2023 Feb;18(1):42-48. doi: 10.1159/000526732. Epub 2022 Sep 14.
8
Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy.血脂异常与接受新辅助化疗的乳腺癌患者的预后不良相关。
BMC Cancer. 2023 Mar 4;23(1):208. doi: 10.1186/s12885-023-10683-y.
9
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world.将HER2低表达乳腺癌的预测和预后数据从临床试验应用到现实世界中。
Front Mol Biosci. 2022 Sep 26;9:996434. doi: 10.3389/fmolb.2022.996434. eCollection 2022.
10
Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis.新辅助化疗治疗乳腺癌中肿瘤浸润淋巴细胞的预测和预后价值:荟萃分析。
Breast. 2022 Dec;66:97-109. doi: 10.1016/j.breast.2022.10.001. Epub 2022 Oct 5.

新辅助治疗局部晚期乳腺癌病例中影响病理完全缓解的因素:一项综合文献综述

Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review.

作者信息

Alamoodi Munaser

机构信息

Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

出版信息

Eur J Breast Health. 2023 Dec 27;20(1):8-14. doi: 10.4274/ejbh.galenos.2023.2023-11-2. eCollection 2024 Jan.

DOI:10.4274/ejbh.galenos.2023.2023-11-2
PMID:38187111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10765459/
Abstract

Determining pathological complete response (pCR) could be an important step in planning individual treatment, hence improving the prognosis in terms of survival. Achieving breast pCR not only improves survival but is also linked to a disease-free axilla, therefore increasing the likelihood of avoiding axillary surgery safely. The current trend in de-escalating axillary management surgically or in applying radiotherapy to the axilla is dependent primarily on breast cancer (BC) patients achieving pCR. Studies have demonstrated that certain characteristics can predict pCR, even though it is still difficult to identify these elements. A review of the literature was carried out to determine these factors and their clinical applications. A search was carried out in the MEDLINE database using PubMed, Google Scholar, and EMBASE. This yielded 1368 studies, of which 60 satisfied the criteria. The studies were categorized according to the subject they dealt with. These parameters included age, race, subtypes, clinicopathological, immunological, imaging, obesity, Ki-67 status, vitamin D, and genetics. These factors, in combination, can be used for specific subtypes to individualize treatment and monitor response to therapy. The predictors of pCR are diverse and should be utilized to personalize patient treatment, ultimately inducing the best outcomes. These determinants can also be employed for monitoring responses to neoadjuvant therapy, thereby adjusting treatment. The development of standardized markers for the diversity of BC subtypes still needs additional future research. These factors must be applied in concert in order to provide optimal results.

摘要

确定病理完全缓解(pCR)可能是规划个体化治疗的重要一步,从而改善生存预后。实现乳腺pCR不仅能提高生存率,还与腋窝无病状态相关,因此增加了安全避免腋窝手术的可能性。目前在手术上降低腋窝处理强度或对腋窝应用放疗的趋势主要取决于乳腺癌(BC)患者是否达到pCR。研究表明,某些特征可以预测pCR,尽管识别这些因素仍然困难。为了确定这些因素及其临床应用,我们进行了文献综述。我们使用PubMed、谷歌学术和EMBASE在MEDLINE数据库中进行了检索。这产生了1368项研究,其中60项符合标准。这些研究根据其涉及的主题进行了分类。这些参数包括年龄、种族、亚型、临床病理、免疫、影像、肥胖、Ki-67状态、维生素D和遗传学。这些因素结合起来,可用于特定亚型以实现个体化治疗并监测治疗反应。pCR的预测因素多种多样,应加以利用以实现患者治疗的个性化,最终诱导出最佳结果。这些决定因素还可用于监测新辅助治疗的反应,从而调整治疗。针对BC亚型多样性的标准化标志物的开发仍需要未来进一步研究。这些因素必须协同应用才能提供最佳结果。